Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of gefitinib in treating patients who have
recurrent and/or metastatic head and neck cancer. Biological therapies such as gefitinib may
interfere with the growth of tumor cells by blocking an enzyme necessary for cell growth.